BRIEF published on 07/07/2025 at 15:05, 8 months 16 days ago Applied DNA Sciences se conforme aux normes de cotation du Nasdaq Biotechnologie Sciences Appliquées De L'ADN Conformité Au Nasdaq Technologies De L'ADN LineaRx
BRIEF published on 07/07/2025 at 15:05, 8 months 16 days ago Applied DNA Sciences Complies with Nasdaq Listing Standards Biotechnology Nasdaq Compliance Applied DNA Sciences DNA Technologies LineaRx
PRESS RELEASE published on 07/07/2025 at 15:00, 8 months 16 days ago Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements Applied DNA Sciences regains compliance with Nasdaq listing rule requiring minimum bid price of $1.00 per share. Company's securities to remain listed on Nasdaq Capital Market Nasdaq Compliance Applied DNA Sciences Nasdaq Capital Market Minimum Bid Price PCR-based DNA Technologies
BRIEF published on 06/17/2025 at 22:15, 9 months 5 days ago Transition de direction chez Applied DNA : le Dr Hayward, PDG, prend sa retraite Biotechnologie Changement De Direction Valeur Actionnariale ADN Appliqué Judy Murrah
BRIEF published on 06/17/2025 at 22:15, 9 months 5 days ago Leadership Transition at Applied DNA as CEO Dr. Hayward Retires Biotechnology Shareholder Value Leadership Change Applied DNA Judy Murrah
PRESS RELEASE published on 06/17/2025 at 22:10, 9 months 5 days ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
BRIEF published on 05/15/2025 at 22:10, 10 months 7 days ago Applied DNA Sciences enregistre une croissance modeste de ses revenus au deuxième trimestre 2025 Croissance Des Revenus Restructuration Stratégique Résultats Financiers Du Deuxième Trimestre Tendances Biopharmaceutiques Technologie De L'ADN
BRIEF published on 05/15/2025 at 22:10, 10 months 7 days ago Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025 Revenue Growth Strategic Restructuring Q2 Financial Results DNA Technology Biopharma Trends
PRESS RELEASE published on 05/15/2025 at 22:05, 10 months 7 days ago Applied DNA Reports Second Quarter Fiscal 2025 Financial Results Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 44% Y/Y increase in LineaRx segment revenues contributing to a 6% total revenue growth. Strategic priorities and financial highlights for Q2 2025 disclosed Financial Results Strategic Priorities Applied DNA Sciences LineaRx Segment Therapeutic DNA Production
BRIEF published on 05/14/2025 at 17:35, 10 months 9 days ago Applied DNA Sciences publiera ses résultats financiers du deuxième trimestre et organisera une mise à jour pour les investisseurs Sciences Appliquées De L'ADN Conférence Téléphonique Pour Les Investisseurs Priorités Stratégiques Rediffusion Du Webcast Résultats Financiers Du Deuxième Trimestre 2025
Published on 03/23/2026 at 14:05, 3 hours 57 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 4 hours 2 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 4 hours 57 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 5 hours 30 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 5 hours 32 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 17:54, 8 minutes ago EQS-Adhoc: net digital AG publishes 2026 forecast with continued growth in revenue and earnings
Published on 03/23/2026 at 17:45, 17 minutes ago Carvolix joins key Euronext indices, marking a new milestone in its capital markets profile.
Published on 03/23/2026 at 17:45, 17 minutes ago Carvolix rejoint des indices clés d’Euronext, marquant une nouvelle étape dans son positionnement sur les marchés financiers.
Published on 03/23/2026 at 17:44, 18 minutes ago Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
Published on 03/23/2026 at 17:00, 1 hour 2 minutes ago Phuket consolide sa position privilégiée pour les familles du monde entier en quête d’un lieu de résidence sûr
Published on 03/23/2026 at 17:45, 17 minutes ago ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 17 minutes ago En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde
Published on 03/23/2026 at 17:45, 17 minutes ago Share buyback for allocation to employees or corporate officers
